Response evaluation for cancer treatment consists primarily of clinical and radiological
assessments. In addition, a limited number of serum biomarkers that assess treatment …

The development of minimally invasive and low-cost assay enabling early diagnosis,
treatment response and prognosis in cancer patients may provide a promising alternative to …

Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer
exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low …

Lung cancer is the leading cause of cancer-related deaths, demanding improvement in
current treatment modalities to reduce the mortality rates. Lung cancer is divided into two …

Background Few studies have demonstrated that the relationship between m6A-related
genes and the prognosis, tumor microenvironment and drug resistance of LC. Methods The …

The progression of cancer is an evolutionary process that is challenging to monitor between
sampling timepoints. However, investigation of cancer evolution over specific time periods is …

Epidermal growth factor receptor (EGFR) mutational testing in advanced non‐small‐cell
lung cancer (NSCLC) is usually performed in tumor tissue, although cfDNA (cell‐free DNA) …

Background Non-small cell lung cancer (NSCLC) remains a significant global health
concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This …

Background: Lung cancer contributes to high cancer mortality worldwide with 80% of total
cases diagnosed as non-small cell lung cancer (NSCLC). Epidermal growth factor receptor …

Background The cobas® epidermal growth factor receptor (EGFR) Mutation Test v2
designed for cell‐free DNA (cf DNA) is approved as a companion diagnostic for osimertinib …